Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus

Asian Journal of Transfusion Science

Volumn 8, Issue 1, 2014, Pages 13-18

  Shyamala, Venkatakrishna ^a  

^a Research Diagnostics Inc   (India)

Author keywords

Donor look back; individual donation nucleic acid technology testing; multi pool nucleic acid technology testing; recipient trace back; transfusion transmitted viral infections; window period and occult infections

Indexed keywords

EID: 84894176567     PISSN: 09736247     EISSN: 19983565     Source Type: Journal    
DOI: 10.4103/0973-6247.126682     Document Type: Review

References (57)

1. Regulatory requirements of blood and/or its components including blood products. Available from: http://cdsco.nic.in/html/guideline.htm. [last accessed on 2013 Oct. 10].
2. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002;42:537-48.
3. Weusten J, Vermeulen M, van Drimmelen H, Lelie N. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51:203-15.
4. Roth WK. Hepatitis B and blood transfusion. ISBT Sci Ser 2007;2:178-83.
5. Vermeulen M, Lelie N, Reddy R. Recent insights in testing for transfusion transmissible viral infections. ISBT Sci Ser 2011;6:229-33.
6. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013;53:1405-15.
7. Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang 2003;84:292-9.
8. http://aidsdatahub.org/en/india-reference-library/item/ 12112-annual-cmis-bulletin-2008-09-national-aids-control-organisationindia-2010, p74 [Last accessed on 2013 Oct. 10].
9. Mathur M, Wanjari K, Turbadkar D. Seroprevalence of HIV, hepatitis C and hepatitis B in multitransfused thalassemics. Indian J Med Microbiol 2008;26:205-6.
10. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
11. Schmidt M, Korn K, Nübling CM, Chudy M, Kress J, Horst HA, et al. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49:1836-44.
12. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, et al. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009;49:289-300.
13. Marwaha N. Whole blood and component use in resource poor settings. Biologicals 2010;38:68-71.
14. Najioullah F, Barlet V, Renaudier P, Guitton C, Crova P, Guérin JC, et al. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol 2004;73:347-9.
15. Nübling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, et al. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49:1850-8.
16. Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, et al. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion 2012;52:431-9.
17. Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M, et al. A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011;51:719-30.
18. Phelps R, Robbins K, Liberti T, Machuca A, Leparc G, Chamberland M, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004;44:929-33.
19. Harritshoj LH, Dickmeiss E, Hansen MB, Ullum H, Jorgensen LB, Gerstoft J. Transfusion-transmitted human immunodeficiency virus infection by a Danish blood donor with a very low viral load in the preseroconversion window phase. Transfusion 2008;48:2026-8.
20. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004;86:171-7.
21. Stramer SL. Current risks of transfusion-transmitted agents: A review. Arch Pathol Lab Med 2007;131:702-7.
22. Kalus U, Edelmann A, Pruss A, Hofmann J, Kiesewetter H, Krüger DH, et al. Noninfectious transfusion of platelets donated before detection of human immunodeficiency virus RNA in plasma. Transfusion 2009;49:435-9.
23. Satake M. Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan. Int J Hematol 2004;80:306-10.
24. Schüttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000;355:41-2.
25. Taylor C, Price TH, Strong DM. Possible HCV transmission from blood screened by pooled nucleic acid testing. Transfusion 2002;42 Suppl:9S S30-030E.
26. Kretzschmar E, Chudy M, Nübling CM, Ross RS, Kruse F, Trobisch H. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: A comparative study with various assays. Vox Sang 2007;92:297-301.
27. Grabarczyk P, Gronowska A, Brojer E, Letowska M, Radziwon P. Sequence analysis confirmation of transfusion-transmitted hepatitis C by red blood cells that tested negative by minipool hepatitis C virus nucleic acid testing. Transfusion 2007;47:1102-4.
28. Gerlich WH, Glebe D, Schüttler CG. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat 2007;14 Suppl 1:16-21.
29. Comanor L, Holland P. Hepatitis B virus blood screening: Unfinished agendas. Vox Sang 2006;91:1-12.
30. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011;100:92-8.
31. Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: Estimated and observed window period risk. Transfusion 2012;52:880-92.
32. Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, et al. Occult hepatitis B virus infection: Detection and significance. Dig Dis 2010;28:116-25.
33. Gerlich WH, Wagner FF, Chudy M, Harritshoj LH, Lattermann A, Wienzek S, et al. HBsAg non-reactive HBV infection in blood donors: Transmission and pathogenicity. J Med Virol 2007;79:S32-6.
34. Garmiri P, Rezvan H, Abolghasemi H, Allain JP. Full genome characterization of hepatitis B virus strains from blood donors in Iran. J Med Virol 2011;83:948-52.
35. González R, Torres P, Castro E, Barbolla L, Candotti D, Koppelman M, et al. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion 2010;50:221-30.
36. Louisirirotchanakul S, Oota S, Khuponsarb K, Chalermchan W, Phikulsod S, Chongkolwatana V, et al. Occult hepatitis B virus infection in Thai blood donors. Transfusion 2011;51:1532-40.
37. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008;49:537-47.
38. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, et al. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006;44:99-107.
39. Mahgoub S, Candotti D, El Ekiaby M, Allain JP. Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol 2011;49:298-306.
40. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, et al. Experience of German Red Cross blood donor services with nucleic acid testing: Results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1558-66.
41. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47:1197-205.
42. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008;48:1022-5.
43. Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, et al. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion 2013;53:1393-404.
44. Makroo RN, Chowdhry M, Bhatia A, Arora B, Rosamma NL. Hepatitis B core antibody testing in Indian blood donors: A doubleedged sword! Asian J Transfus Sci 2012;6:10-3.
45. Vivekanandan P, Abraham P, Sridharan G, Chandy G, Daniel D, Raghuraman S, et al. Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin Infect Dis 2004;38:e81-6.
46. Kumar A, Dwivedi M, Misra SP, Misra V, Narang S, Pandey R, et al. Distribution of hepatitis B virus genotypes and its association with severity of liver disease in patients with chronic hepatitis B in Uttar Pradesh, India. Indian J Virol 2011;22:24-8.
47. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001;41:878-84.
48. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011;364:236-47.
49. Shan H, Ren FR, Zhao HY, Zhang YZ, Wen GX, Yao FZ, et al. A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing. Transfusion 2007;47:2011-6.
50. Yang MH, Li L, Hung YS, Hung CS, Allain JP, Lin KS, et al. The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion 2010;50:65-74.
51. Vermeulen M, Coleman C, Mitchel J, Reddy R, van Drimmelen H, Fickett T, et al. Comparison of human immunodeficiency virus assays in window phase and elite controller samples: Viral load distribution and implications for transmission risk. Transfusion 2013;53:2384-98.
52. Grabarczyk P, Letowska M, Kopacz A, Liszewski G, Sulkowska E, Brojer E. Effectiveness of various minipool nucleic acid test systems for hepatitis B virus detection in blood donors. Transfusion 2009;49:1494-5.
53. Vermeulen M, Coleman C, Mitchel J, Reddy R, van Drimmelen H, Ficket T, et al. Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections. Transfusion 2013;53:2459-66.
54. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, et al. International survey on NAT testing of blood donations: Expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
55. Makroo RN, Choudhury N, Jagannathan L, Parihar-Malhotra M, Raina V, Chaudhary RK, et al. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 and hepatitis B and C viruses in Indian blood donors. Indian J Med Res 2008;127:140-7.
56. Agarwal N, Chatterjee K, Coshic P, Borgohain M. Nucleic acid testing for blood banks: An experience from a tertiary care centre in New Delhi, India. Transfus Apher Sci 2013;49:482-4.
57. van Hulst M, Hubben GA, Sagoe KW, Promwong C, Permpikul P, Fongsatitkul L, et al. Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: A global model applied to Ghana, Thailand, and the Netherlands. Transfusion 2009;49:2729-42.